ReviewCancer science2017

Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy.

Hidemitsu Kitamura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.